Protein array technology

Novagen (ProteoPlex ), S S (FAST Quant), BioSource (Cartesian Array ), and BD Biosciences (BD Clontech Ab Microarrays) have introduced or will soon introduce protein microarray slide formatted products in which antibodies are directly immobilized. Beckman Coulter s protein array products for performing micro-ELlSAS in standard 96-well plate formats are based upon the self-assembly (by hybridization) of oligonucleotide-antibody conjugates to complementary oligonucleotides arrayed in individual wells. HTG s protein array technology was described previously. 

Kricka, L.J., et al. (2006) Current perspectives in protein array technology. Ann Clin Biochem. 43, 457-67. 

Protein Array Technology The Tool to Bridge Genomics and Proteomics... 

A very crucial part in protein array technology is played by the deposition of the proteins on a suitable surface. As described earlier, the nature of the surface with influencing parameters Uke charge, viscosity, pore size, pH, binding capacity, imspecific protein binding, etc is essential for the generation of protein arrays that contain the proteins in an biologically active shape and form. New sur-... 

Eickhoff, H., Konthur, Z., Lueking, A., Lehrach, K, Walter, G., Nordhpff, ., Nyarsik, L Bussow, K. Protein Array Technology The Tool to Bridge Genomics and Proteomics. Vol. 77, p. 103... 

Although virtually all drug targets are protein based, the inference that protein expression levels can be accurately (if indirectly) detected/measured via DNA array technology is a false one, as ... 

He, M. and Taussig, M.J., DiscernArray technology a cell-free method for the generation of protein arrays from RCR DN A,. Immunol. Meth., 274,265-270,2003. 

This book picks up the array technology journey from the mid-1990s with the introduction of microarray-based gene expression analysis. The global analysis of genes by microarrays has provided a fresh and exciting view of the cellular process. More importantly, it enabled others to consider similar utility in various "omic" fields. Hence, we have witnessed the emergence of protein arrays to address proteomics. 

Robert (Bob) Matson, Ph.D., is a senior staff scientist in the Advanced Technology Center at Beckman Coulter, Inc., Fullerton, California. He has been involved in the development of both nucleic acid and protein array-based technology for the past 13 years. His initial introduction to array technology began in collaboration with Sir Edwin Southern in developing an in situ oligonucleotide array synthesis platform for the corporation. Later work by Dr. Matson and his research team produced some of the first plastic microplate-based microarrays. Beckman Coulter recently launched the pi te based upon the microplate "array of arrays" concept. 

The term reverse phase protein microarray was first coined in 2001 by Paweletz et al. (5) in the landmark paper which introduced the platform and demonstrated its utility for analyzing proteins derived from laser capture microdissected (LCM) prostate cancer. RPMAs have also been referred to by other names in the literature including lysate arrays, reverse phase lysate arrays, protein microarrays, and reverse phase protein arrays (6). A very nice historical perspective on the development of RPJMA technology is presented in a review by Mueller et al. (6). A detailed description of the methods for performing RPMA is beyond the scope of this chapter and would be redundant because there are... 

---